A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

The National Guideline Clearinghouse™ currently contains 2005 guidelines that have been superceded.

Philippine Academy of Ophthalmology

1. Clinical practice guideline for the management of cataract among adults. (NGC-2189)
   • Philippine Academy of Ophthalmology. Clinical practice guideline for the management of cataract among adults. Philippines: Philippine Academy of Ophthalmology; 2001. 27 p. [73 references]

   CURRENT NGC SUMMARY: (1) Clinical practice guideline for the management of cataract among adults. (2) Updated recommendation #14. (NGC-4559)

Program in Evidence-based Care

1. Adjuvant systemic chemotherapy, following surgery and external beam radiotherapy, for adults with newly diagnosed malignant glioma. (NGC-3654)
   • Neuro-Oncology Disease Site Group. Perry J, Zuraw L. Adjuvant systemic chemotherapy, following surgery and external beam radiotherapy, for adults with newly diagnosed malignant glioma [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2004 Jun [online update]. 14 p. (Practice guideline report; no. 9-2). [32 references]

   CURRENT NGC SUMMARY: Adjuvant systemic chemotherapy, following surgery and external beam radiotherapy, for adults with newly diagnosed malignant glioma: a clinical practice guideline. (NGC-5092)

2. Adjuvant therapy for stage II colon cancer following complete resection. (NGC-3462)
   • Gastrointestinal Disease Site Group. Figueredo A, Germond C, Maroun J, Browman G, Walker-Dilks C, Wong S. Adjuvant therapy for stage II colon cancer following complete resection [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2000 Dec [online update]. 30 p. (Practice guideline report; no. 2-1). [70 references]

   CURRENT NGC SUMMARY: Adjuvant systemic chemotherapy for stage II and III colon cancer following complete resection: guideline recommendations. (NGC-6528)

3. Adjuvant therapy for stage III colon cancer following complete resection. (NGC-3463)
   • Gastrointestinal Cancer Disease Site Group. Figueredo A, Fine S, Maroun J, Walker-Dilks C, Wong S. Adjuvant therapy for stage III colon cancer following complete resection [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2000 Dec [online update]. 34 p. (Practice guideline report; no. 2-2). [81 references]

   CURRENT NGC SUMMARY: Adjuvant systemic chemotherapy for stage II and III colon cancer following complete resection: guideline recommendations. (NGC-6528)

4. Chemotherapy in stage IV (metastatic) non-small cell lung cancer. (NGC-2422)
   • Cancer Care Ontario Practice Guideline Initiative (CCOPGI). Chemotherapy in stage IV (metastatic) non-small cell lung cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2002 Jan [online update]. Various p. (Practice guideline; no. 7-2). [28 references]

   CURRENT NGC SUMMARY: Chemotherapy in stage IV (metastatic) non-small cell lung cancer. (NGC-5093)

5. Combined modality radiotherapy and chemotherapy in the non-surgical management of localized carcinoma of the esophagus. (NGC-3264)
   • Gastrointestinal Cancer Disease Site Group. Wong RK, Malthaner RA, Zuraw L, Rumble RB. Combined modality radiotherapy and chemotherapy in the non-surgical management of localized carcinoma of the esophagus [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2003 Aug 18 [online update]. 22 p. (Practice guideline; no. 2-12). [49 references]

   CURRENT NGC SUMMARY: Combined modality radiotherapy and chemotherapy in the non-surgical management of localized carcinoma of the esophagus. (NGC-4572)

6. First-line chemotherapy for postoperative patients with stage II, III or IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. (NGC-3458)
   • Gynecology Disease Site Group. Covens A, Carey M, Bryson P, Verma S, Fung Kee Fung M. First-line chemotherapy for postoperative patients with stage II, III or IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2004 Jan [online update]. 37 p. (Practice guideline report; no. 4-1-2). [64 references]

   CURRENT NGC SUMMARY: First-line chemotherapy for postoperative patients with stage II, III or IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. (NGC-3772)

7. Management of ductal carcinoma in situ of the breast. (NGC-2927)
   • Breast Cancer Disease Site Group. Management of ductal carcinoma in situ of the breast [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2003 Jan [online update]. 18 p. (Practice guideline; no. 1-10). [46 references]

   CURRENT NGC SUMMARY: Management of ductal carcinoma in situ of the breast: a clinical practice guideline. (NGC-5344)

8. Management of single brain metastases. (NGC-3843)
   • Neuro-oncology Disease Site Group. Mintz AP, Perry J, Cairncross G, Chambers A. Management of single brain metastases [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2004 Aug 17. 25 p. (Practice guideline report; no. 9-1). [50 references]

   CURRENT NGC SUMMARY: Management of single brain metastases: a clinical practice guideline. (NGC-5651)

9. Neoadjuvant or adjuvant therapy for resectable esophageal cancer. (NGC-4436)
   • Gastrointestinal Cancer Disease Site Group. Malthaner RA, Wong RKS, Rumble RB, Zuraw L. Neoadjuvant or adjuvant therapy for resectable esophageal cancer. Toronto (ON): Cancer Care Ontario (CCO); 2005 Apr 13. 35 p. (Practice guideline report; no. 2-11). [65 references]

   CURRENT NGC SUMMARY: Preoperative or postoperative therapy for resectable esophageal cancer: guideline recommendations. (NGC-6707)

10. Oral capecitabine (Xeloda™) in the first-line treatment of metastatic colorectal cancer. (NGC-3465)
    • Gastrointestinal Cancer Disease Site Group. Kocha W, Maroun J, Jonker D, Rumble RB, Zuraw L. Oral capecitabine (Xeloda) in the first-line treatment of metastatic colorectal cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2003 Dec 5. 19 p. (Practice guideline report; no. 2-15). [26 references]

    CURRENT NGC SUMMARY: Oral capecitabine (Xeloda) in the first-line treatment of metastatic colorectal cancer: a clinical practice guideline. (NGC-5094)

11. Postoperative adjuvant radiation therapy in stage II or IIIA completely resected non-small cell lung cancer. (NGC-3262)
    • Lung Cancer Disease Site Group. Okawara G, Ung YC, Markman BR, Mackay JA, Evans WK. Postoperative adjuvant radiation therapy in stage II or IIIA completely resected non-small cell lung cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2003 Aug [online update]. 15 p. (Practice guideline; no. 7-1-1). [14 references]

    CURRENT NGC SUMMARY: Postoperative adjuvant radiation therapy in stage II or IIIA completely resected non-small cell lung cancer. (NGC-4124)

12. Postoperative adjuvant radiotherapy and/or chemotherapy for resected stage II or III rectal cancer. (NGC-2508)
    • Cancer Care Ontario Practice Guideline Initiative (CCOPGI). Postoperative adjuvant radiotherapy and/or chemotherapy for resected stage II or III rectal cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2001 Dec. Various p. (Practice guideline; no. 2-3). [51 references]

    CURRENT NGC SUMMARY: Preoperative or postoperative therapy for the management of patients with stage II or III rectal cancer: guideline recommendations. (NGC-6706)

13. Primary treatment for locally advanced cervical cancer: concurrent platinum-based chemotherapy and radiation. (NGC-3088)
    • Gynecology Cancer Disease Site Group. Lukka H, Hirte H, Fyles A, Thomas G, Fung Kee Fung M. Primary treatment for locally advanced cervical cancer: concurrent platinum-based chemotherapy and radiation [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2003 Jun [online update]. 25 p. (Practice guideline; no. 4-5). [25 references]

    CURRENT NGC SUMMARY: Primary treatment for locally advanced cervical cancer: concurrent platinum-based chemotherapy and radiation. (NGC-3773)

14. Radiotherapy for newly diagnosed malignant glioma in adults. (NGC-3775)
    • Neuro-oncology Disease Site Group. Laperriere N, Perry J, Zuraw L. Radiotherapy for newly diagnosed malignant glioma in adults [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2004 Jun [online update]. 27 p. (Practice guideline report; no. 9-3). [80 references]

    CURRENT NGC SUMMARY: Radiotherapy for newly diagnosed malignant glioma in adults: a clinical practice guideline. (NGC-4954)

15. Rituximab in lymphoma and chronic lymphocytic leukemia: a clinical guideline (NGC-4353)
    • Hematology Disease Site Group. Imrie K, Stevens A, Meyer R. Rituximab in lymphoma and chronic lymphocytic leukemia: a clinical practice guideline. Toronto (ON): Cancer Care Ontario (CCO); 2005 Feb 17. 43 p. (Evidence-based series; no. 6-8). [51 references]

    CURRENT NGC SUMMARY: Rituximab in lymphoma and chronic lymphocytic leukemia: a clinical practice guideline. (NGC-5095)

16. Screening for skin cancer: a clinical practice guideline. (NGC-5025)
    • From L, Marrett L, Johnston M, Mai V, Fong J, Rosen C, Bak K, Sibbald G, Skin Cancer Screening Guideline Panel. Screening for skin cancer: a clinical practice guideline. Toronto (ON): Cancer Care Ontario (CCO); 2006 Mar 15. 32 p. (Evidence-based series; no. 15-1). [70 references]

    CURRENT NGC SUMMARY: Screening for skin cancer: a clinical practice guideline. (NGC-5888)

17. Symptomatic treatment of radiation-induced xerostomia in head and neck cancer patients. (NGC-2760)
    • Hodson DI, Haines T, Berry M, Johnston M, Head and Neck Cancer Disease Site Group. Symptomatic treatment of radiation-induced xerostomia in head and neck cancer patients [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2002 Oct [online update]. 15 p. (Practice guideline; no. 5-5). [28 references]

    CURRENT NGC SUMMARY: Symptomatic treatment of radiation-induced xerostomia in head and neck cancer patients. (NGC-3526)

18. Systemic adjuvant therapy for patients at high risk for recurrent melanoma. (NGC-3774)
    • Melanoma Disease Site Group. Systemic adjuvant therapy for patients at high risk for recurrent melanoma [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2004 Jun 30. 33 p. (Practice guideline report; no. 8-1). [59 references]

    CURRENT NGC SUMMARY: Systemic adjuvant therapy for patients at high risk for recurrent melanoma: a clinical practice guideline. (NGC-5020)

19. The role of aromatase inhibitors in adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: a clinical practice. (NGC-4716)
    • Eisen A, Trudeau M, Sinclair S, Breast Cancer Disease Site Group. The role of aromatase inhibitors in adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: a clinical practice guideline. Toronto (ON): Cancer Care Ontario (CCO); 2005 Oct 25. Various p. (Evidence-based series; no. 1-18). [42 references]

    CURRENT NGC SUMMARY: The role of aromatase inhibitors in adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: guideline recommendations. (NGC-6433)

20. The role of Bevacizumab (Avastin™) combined with chemotherapy in the treatment of patients with advanced colorectal cancer: a clinical practice guideline. (NGC-4866)
    • Welch S, Kocha W, Rumble RB, Spithoff K, Maroun J, Gastrointestinal Cancer Disease Site Group. The role of bevacizumab (Avastin) combined with chemotherapy in the treatment of patients with advanced colorectal cancer. Toronto (ON): Cancer Care Ontario (CCO); 2005 Dec 12. 23 p. (Evidence-based series; no. 2-25). [18 references]

    CURRENT NGC SUMMARY: The role of Bevacizumab (Avastin®) combined with chemotherapy in the treatment of patients with advanced colorectal cancer: a clinical practice guideline. (NGC-6314)

21. The role of chemotherapy with radiotherapy in the management of patients with newly diagnosed locally advanced squamous cell or undifferentiated nasopharyngeal cancer. (NGC-3527)
    • Head and Neck Cancer Disease Site Group. Thephamongkhol K, Browman G, Hodson I, Oliver T, Zuraw L. The role of chemotherapy with radiotherapy in the management of patients with newly diagnosed locally advanced squamous cell or undifferentiated nasopharyngeal cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2004 Mar [online update]. 20 p. (Practice guideline report; no. 5-7). [25 references]

    CURRENT NGC SUMMARY: Chemotherapy with radiotherapy for nasopharyngeal cancer. (NGC-4357)

22. The role of erythropoietin in the management of cancer patients with non-hematologic malignancies receiving chemotherapy. (NGC-2969)
    • Systematic Treatment Disease Site Group. The role of erythropoietin in the management of cancer patients with non-hematologic malignancies receiving chemotherapy [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2003 Mar [online update]. 25 p. (Practice guideline; no. 12-1). [55 references]

    CURRENT NGC SUMMARY: The role of erythropoietin in the management of cancer patients with non-hematologic malignancies receiving chemotherapy. (NGC-4311)

23. The role of gemcitabine in the management of metastatic breast cancer: a clinical practice guideline. (NGC-5099)
    • Dent S, Messersmith H, Trudeau M, Breast Cancer Disease Site Group. The role of gemcitabine in the management of metastatic breast cancer: a clinical practice guideline. Toronto (ON): Cancer Care Ontario (CCO); 2006 Jun 27. 36 p. (Evidence-based series; no. 1-12). [148 references]

    CURRENT NGC SUMMARY: The role of gemcitabine in the management of metastatic breast cancer: a clinical practice guideline. (NGC-5583)

24. The role of octreotide in the management of patients with cancer. (NGC-3260)
    • Systemic Treatment Disease Site Group. Major P, Figueredo A, Tandan V, Bramwell V, Charette M, Oliver T. The role of octreotide in the management of patients with cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2003 May 7. 27 p. (Practice guideline; no. 12-7). [51 references]

    CURRENT NGC SUMMARY: The role of octreotide in the management of patients with cancer. (NGC-4042)

25. The role of oxaliplatin combined with 5-fluorouracil and folinic acid in the first and second-line treatment of advanced colorectal cancer: a clinical practice guideline. (NGC-5345)
    • Jonker D, Rumble RB, Maroun J, Gastrointestinal Cancer Disease Site Group. The role of oxaliplatin combined with 5-fluorouracil and folinic acid in the first and second-line treatment of advanced colorectal cancer: a clinical practice guideline. Toronto (ON): Cancer Care Ontario (CCO); 2005 Jun 2. 27 p. (Evidence-based series; no. 2-22). [36 references]

    CURRENT NGC SUMMARY: The role of oxaliplatin combined with 5-fluorouracil and folinic acid in the first and second-line treatment of advanced colorectal cancer: a clinical practice guideline. (NGC-6242)

26. The role of single-agent docetaxel (Taxotere®) as a second-line treatment for advanced non-small-cell lung cancer. (NGC-4435)
    • Lung Cancer Disease Site Group. The role of single-agent docetaxel (Taxotere) as a second-line treatment for advanced non-small-cell lung cancer. Toronto (ON): Cancer Care Ontario (CCO); 2005 Jan. 14 p. (Practice guideline report; no. 7-7-2). [16 references]

    CURRENT NGC SUMMARY: Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a clinical practice guideline. (NGC-4953)

27. The use of preoperative radiotherapy in the management of patients with clinically resectable rectal cancer. (NGC-3461)
    • Figueredo A, Zuraw L, Wong RK, Agboola O, Rumble RB, Tandan V. The use of preoperative radiotherapy in the management of patients with clinically resectable rectal cancer: a practice guideline. 2003 Nov 24;1(1):1. PubMed
    
    
    
    • Gastrointestinal Cancer Disease Site Group. Figueredo A, Zuraw L, Wong RK, Agboola O, Rumble RB, Tandan V. The use of preoperative radiotherapy in the management of patients with clinically resectable rectal cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2004 Jan [online update]. 29 p. (Practice guideline report; no. 2-13). [52 references]

    CURRENT NGC SUMMARY: Preoperative or postoperative therapy for the management of patients with stage II or III rectal cancer: guideline recommendations. (NGC-6706)

28. Unresected stage III non-small cell lung cancer. (NGC-2928)
    • Lung Cancer Disease Site Group. Unresected stage III non-small cell lung cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2003 Jan [online update]. 22 p. (Practice guideline; no. 7-3). [52 references]

    CURRENT NGC SUMMARY: Management of unresected stage III non-small cell lung cancer: a clinical practice guideline. (NGC-5650)

29. Use of bisphosphonates in women with breast cancer. (NGC-2931)
    • Breast Cancer Disease Site Group. Use of bisphosphonates in patients with breast cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2002 Dec [online update]. 23 p. (Practice guideline; no. 1-11). [59 references]

    CURRENT NGC SUMMARY: Use of bisphosphonates in women with breast cancer. (NGC-3770)

30. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. (NGC-2584)
    • Cancer Care Ontario Practice Guideline Initiative (CCOPGI). Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2002 Jun [online update]. Various p. (Practice guideline; no. 12-5). [23 references]

    CURRENT NGC SUMMARY: Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. (NGC-3488)

31. Use of gemcitabine in the treatment of advanced pancreatic adenocarcinoma. (NGC-3348)
    • Gastrointestinal Cancer Disease Site Group. Germond C, Maroun J, Moore M, Zwaal C, Wong S. Use of gemcitabine in the treatment of advanced pancreatic adenocarcinoma [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2003 Jun 24 [online update]. 15 p. (Practice guideline report; no. 2-10). [19 references]

    CURRENT NGC SUMMARY: Use of gemcitabine in the treatment of advanced pancreatic adenocarcinoma. (NGC-5096)

32. Use of irinotecan in the treatment of metastatic colorectal carcinoma. (NGC-3464)
    • Gastrointestinal Cancer Disease Site Group. Figueredo A, Moore M, Germond C, Kocha W, Maroun J, Zwaal C. Use of irinotecan in the treatment of metastatic colorectal carcinoma [full report]. Toronto (ON): Cancer Care Ontario (CCO); 2000 Dec [online update]. 15 p. (Practice guideline report; no. 2-16). [20 references]

    CURRENT NGC SUMMARY: Use of irinotecan in the second-line treatment of metastatic colorectal carcinoma. (NGC-4358)

33. Use of raltitrexed (Tomudex) in the management of metastatic colorectal carcinoma. (NGC-2926)
    • Gastrointestinal Cancer Disease Site Group. Use of raltitrexed (Tomudex) in the management of metastatic colorectal cancer. Toronto (ON): Cancer Care Ontario (CCO); 2003 Feb [online update]. 16 p. (Practice guideline; no. 2-17). [22 references]

    CURRENT NGC SUMMARY: Use of raltitrexed (Tomudex) in the management of metastatic colorectal cancer. (NGC-4434)

Public Health Service (U.S.)

1. Treating tobacco use and dependence. A clinical practice guideline. (NGC-1586)
   • U.S. Department of Health and Human Services, Public Health Service. Fiore MC, Bailey WC, Cohen SJ, et al. Treating tobacco use and dependence. Clinical practice guideline. Rockville (MD): U.S. Department of Health and Human Services, Public Health Service; 2000 Jun. 197 p. [311 references]

   CURRENT NGC SUMMARY: Treating tobacco use and dependence: 2008 update. (NGC-6444)